Patents Examined by Ganapathy Krishnan
  • Patent number: 10842883
    Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-?-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bioavailability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.
    Type: Grant
    Filed: April 7, 2020
    Date of Patent: November 24, 2020
    Assignee: ALTERGON S.A.
    Inventors: Alberto Bernareggi, Nadia Puppini, Alessandro Nencioni
  • Patent number: 10836783
    Abstract: Though 3?,5?-cyclic diadenylic acid was conventionally provided only as a freeze-dried product, a solid material other than a freeze-dried product and a manufacturing method thereof is provided. By a step of adding acid to an aqueous solution of 3?,5?-cyclic diadenylic acid so as to lower pH to 1 to 3, an inclusion compound of 3?,5?-cyclic diadenylic acid can be obtained. Said manufacturing method is an extremely simple and easy method and does not need a special machine or the like.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: November 17, 2020
    Assignee: Yamasa Corporation
    Inventors: Hisaki Tanaka, Kazuya Ishige
  • Patent number: 10822430
    Abstract: The invention relates to glycosaminoglycan derivatives, endowed with heparanase inhibitory activity and antitumor activity, bearing carboxylate groups in positions 2 and 3 of at least part of the glycosaminoglycan residues, and to the process for preparing the same. The glycosaminoglycan derivatives of the present invention are generated starting from natural or synthetic glycosaminoglycans, preferably heparin or low molecular weight heparin, optionally 2-O- and 2N-desulfated by two steps of oxidation. By the first oxidation, adjacent diols and optionally adjacent OH/NH2 of the glycosaminoglycan residues are converted to aldehydes and by the second oxidation said dialdehydes are converted to carboxylate groups. The first oxidation preferably leads to the cleavage of C2-C3 linkage of the ring of oxidable residues. The invention further relates to a process for the preparation of said glycosaminoglycan derivatives and further to their use as active ingredients of medicaments.
    Type: Grant
    Filed: October 22, 2014
    Date of Patent: November 3, 2020
    Assignee: Novahealth Biosystems, LLC
    Inventors: Giangiacomo Torri, Annamaria Naggi
  • Patent number: 10822367
    Abstract: The present invention relates to a pharmaceutical composition comprising an acanthoside B compound as an effective ingredient for preventing or treating dementia or for improving a cognitive function. In the present invention, a desalted glasswort extract, and acanthoside B, which is isolated from the extract and acts as an effective ingredient inhibitory of acetylcholine esterase, were found to have an excellent neuroprotective activity through the inhibition of neuroinflammation and to improve memory retention and remarkably enhance spatial cognitive ability as measured by passive avoidance test and Y-maze test in a scopolamine-induced amnesic animal model. The acanthoside B or glasswort extract of the present invention can be applied to a pharmaceutical composition for preventing or treating dementia, a pharmaceutical composition for improving a cognitive function, or a health functional food or feed for improving memory retention and cognitive function.
    Type: Grant
    Filed: May 14, 2018
    Date of Patent: November 3, 2020
    Assignee: PHYTO CORPORATION INC.
    Inventors: Deuk-Hoi Kim, Mee-Hyang Kweon, Eun-Ah Cho, Joon Soo Kim, Hyun Joo Yoon, Seon Yeong Park
  • Patent number: 10815261
    Abstract: Various ingredients and compositions are prepared from Stevia rebaudiana Bertoni plant. The compositions can be used as bulking agents, and sweeteners in foods, beverages, cosmetics and pharmaceuticals.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: October 27, 2020
    Assignee: PureCircle Sdn Bhd
    Inventor: Avetik Markosyan
  • Patent number: 10799592
    Abstract: The invention provides compositions featuring chitosan and methods for using such compositions for the local delivery of biologically active agents to an open fracture, complex wound or other site of infection. Advantageously, the degradation and drug elution profiles of the chitosan compositions can be tailored to the needs of particular patients at the point of care (e.g., in a surgical suite, clinic, physician's office, or other clinical setting).
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: October 13, 2020
    Assignee: UNIVERSITY OF MEMPHIS RESEARCH FOUNDATION
    Inventors: Warren O. Haggard, Scott P. Noel, Joel D. Bumgardner
  • Patent number: 10787693
    Abstract: Single-chain ?-glucans can be obtained by hydrothermal treatment of a solution containing (1,3)(1,6)-?-glucan for a predetermined time in a temperature range of from 145° C. to 200° C. at a pressure at or above the saturated vapor pressure at the treatment temperature. ?-Glucans capable of maintaining a single-chain state for an extended period of time can be produced without chemical treatment.
    Type: Grant
    Filed: December 14, 2016
    Date of Patent: September 29, 2020
    Assignee: ITOCHU SUGAR CO., LTD.
    Inventors: Nobuhiro Kondo, Katsuki Hirabayashi
  • Patent number: 10787479
    Abstract: A crystal of free acid of 3?,5?-cyclic diguanylic acid containing no metal salt with cobalt, magnesium or the like is provided. A method is sought for obtaining said crystal in a large amount and with ease. By a manufacturing method comprising a step of adding acid to an aqueous solution of 3?,5?-cyclic diguanylic acid so as to lower pH to 1 to 3, crystals of 3?,5?-cyclic diguanylic acid can be obtained in a large amount with ease. Said crystals are free acid crystals which do not contain a metal salt with cobalt, magnesium or the like.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: September 29, 2020
    Assignee: Yamasa Corporation
    Inventors: Hisaki Tanaka, Kazuya Ishige
  • Patent number: 10787476
    Abstract: An object of the present invention is to provide glycoamino acid as an amino acid precursor with improved properties (particularly water-solubility, stability in water, bitter taste etc.). The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the DESCRIPTION, or a salt thereof.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: September 29, 2020
    Assignee: AJINOMOTO CO., INC.
    Inventors: Wataru Kurosawa, Risa Ubagai
  • Patent number: 10781269
    Abstract: A nacre-mimetic environmentally friendly composite membrane with an “interpenetrating petal” structure and a preparation method thereof. Materials for preparing the composite membrane include magadiite, CMC and a bis-silane coupling agent. The composite membrane according to the present invention has an “interpenetrating petal” stable structure with non-parallel petal-shaped lamellar structure. In addition, inorganic sheets intersperse with each other to form an interlock.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: September 22, 2020
    Assignee: SOUTH CHINA UNIVERSITY OF TECHNOLOGY
    Inventors: Mingliang Ge, Mingyi Du, Yanwu Wang
  • Patent number: 10765616
    Abstract: Described herein are methods and compositions that contain a soluble polyglucosamine or polyglucosamine derivative for use in oral health. The compositions are useful for, e.g., reducing bacteria (e.g., by clumping and removing) or disrupting a biofilm in the mouth of a subject, reducing dry mouth, and reducing oral inflammation.
    Type: Grant
    Filed: April 9, 2018
    Date of Patent: September 8, 2020
    Assignee: SYNEDGEN, INC.
    Inventors: Stacy M. Townsend, Shenda M. Baker, William P. Wiesmann
  • Patent number: 10765697
    Abstract: Assays, methods and kits for predicting a subject's (e.g., human) risk of primary glomerulopathy, secondary glomerulopathy or recurrence (e.g., post-transplant recurrence) of any glomerular disease include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Assays for predicting if a diabetic subject will develop kidney disease or a patient with FSGS will develop recurrent disease after transplant also include examining cells for the presence or absence of cytoskeletal disruptions or rearrangements and examining cells for modulation of expression and/or activity of markers such as SMPDL-3b. Also described herein are compositions and methods for treating and preventing the aforementioned disorders.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: September 8, 2020
    Assignee: L & F RESEARCH LLC
    Inventors: Alessia Fornoni, Sandra Merscher-Gomez
  • Patent number: 10758561
    Abstract: Disclosed are compositions comprising synergic combinations of xyloglucans and plant or animal proteins, which are useful in the treatment of intestinal disorders.
    Type: Grant
    Filed: July 17, 2018
    Date of Patent: September 1, 2020
    Assignee: NOVINTETHICAL PHARMA SA
    Inventors: Miguel Angel Alonso Cohen, Michele Giuseppe Di Schiena, Marco Di Fulvio
  • Patent number: 10745432
    Abstract: An object of the present invention is to provide a crystal of 6?-sialyllactose (hereinafter, referred to as 6SL) sodium salt, which is easily handled, and has high storage stability at normal temperature as well as under high temperature conditions, and provide a production process thereof. The present invention relates to a crystal of 6SL sodium salt and a process for producing the crystal.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: August 18, 2020
    Assignee: KYOWA HAKKO BIO CO., LTD.
    Inventors: Masahiro Abe, Tomoya Yokoi, Sotaro Sanpei, Kazunari Fukumoto, Hiroshi Nagano
  • Patent number: 10736888
    Abstract: The invention provides a combination comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable derivative thereof, mupirocin or a pharmaceutically acceptable derivative thereof and neomycin or a pharmaceutically acceptable derivative thereof. This triple combination is particularly useful for the treatment and/or prevention of microbial infections.
    Type: Grant
    Filed: October 20, 2016
    Date of Patent: August 11, 2020
    Assignee: HELPERBY THERAPEUTICS LIMITED
    Inventors: Anthony Coates, Yanmin Hu
  • Patent number: 10729709
    Abstract: Provided herein are pharmaceutically acceptable compositions containing macrolide antibiotics, in particular azithromycin. In particular, compositions containing azithromycin with low toxicity, especially for administration to felines, are provided herein.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 4, 2020
    Assignee: Piedmont Animal Health Inc.
    Inventors: Neil E. Paulsen, Gail L. Dempsey, Michael S. Daniel, Tiffany G. Tomlinson, Douglas Hepler, Raymond Petzold
  • Patent number: 10723751
    Abstract: Provided are cyanogenic compositions for treating diseases, such as infectious diseases.
    Type: Grant
    Filed: January 16, 2019
    Date of Patent: July 28, 2020
    Inventor: Laszlo Sichtnik
  • Patent number: 10722574
    Abstract: The present invention relates to beta-glycolipid derivatives, their preparation and use as adjuvants in vaccines, as being suitable for being co-administered with antigens for vaccine prophylaxis and therapy. In certain embodiments, the beta-glycolipid derivatives of the invention also in their salified or complex form, are suitable for being co-administered with antigens for both therapeutic and prophylactic purposes or for vaccine prophylaxis and therapy.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 28, 2020
    Assignee: CONSIGLIO NAZIONALE DELLE RICERCHE
    Inventors: Angelo Fontana, Emiliano Manzo, Adele Cutignano, Raffaele De Palma
  • Patent number: 10722575
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 28, 2020
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Patent number: 10716803
    Abstract: Described herein are methods of treating a subject that has been or will be exposed to radiation, trauma or shock, the method comprising identifying a subject that has been or will be exposed to radiation, and treating the subject with a compound that treats, reduces the severity or delays the onset of sepsis or reduces the likelihood of mortality in a subject upon administration of a therapeutically effective amount the compound to the subject.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 21, 2020
    Assignee: SYNEDGEN, INC.
    Inventors: Shenda M. Baker, William P. Wiesmann